

Attorney Docket No. CCC1P020**DECLARATION****JOINT INVENTORS
ORIGINAL/SUBSTITUTE/CIP**

As a below named inventor, I hereby declare that: my residence, post office address, and citizenship are as stated below next to my name. I believe I am the original, first, and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

WIRELESS UNIVERSAL SERIAL BUS LINK FOR A COMPUTER SYSTEMas described in the specification ☐ attached or ☐ of patent Application Serial No. _____

filed _____ and amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above; that I do not know and do not believe the same was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application; that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application in any country foreign to the United States of America on an application filed by me or my legal representative or assigns more than twelve months prior to this application; and that I acknowledge the duty to disclose information of which I am aware which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations § 1.56(a). Such information is material when it is not cumulative to information already of record or being made of record in the application, and

- (1) it establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
 (2) it refutes, or is inconsistent with, a position the applicant has taken or may take in:

- (i) opposing an argument of unpatentability relied on by the Office, or
 (ii) asserting an argument of patentability.

I hereby claim foreign priority benefits under Title 35, United States Code § 119 of any foreign application(s) for patent or inventor's certificates listed below and have also identified below any foreign application(s) having a filing date before that of the application(s) on which priority is claimed:

COUNTRY	APPLICATION NUMBER	DATE OF FILING	PRIORITY CLAIMED UNDER 35 USC 119
			<input type="checkbox"/> YES <input type="checkbox"/> NO

I hereby claim the benefit under Title 35 United States Code § 120 of any United States application(s) listed below and, insofar as any subject matter of any claim of this application is not disclosed in the prior United States Application, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations § 1.56(a) which occurred between the filing date of the prior application and the national PCT international filing date of this application:

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF SOLE OR FIRST INVENTOR Rabah S. Hamdi		INVENTOR'S SIGNATURE <i>Rabah Hamdi</i>	DATE 3/27/98
RESIDENCE 19949 Rammel N. Houston Road, Apt #1618, Houston, TX 77066 5800 Hollister ST. # 1316, Houston, Tex. 77040		CITIZENSHIP USA	
POST OFFICE ADDRESS SAME			
FULL NAME OF SECOND JOINT INVENTOR Edward E. Olkkola		INVENTOR'S SIGNATURE <i>EDWARD OLKKOLA</i>	DATE 3/27/98
RESIDENCE 22703 Laurelwood, Tomball, TX 77375		CITIZENSHIP USA	
POST OFFICE ADDRESS SAME			

96753-4425060



တတိယ

Serial No.: Unassigned

For: WIRELESS UNIVERSAL SERIAL BUS LINK
FOR A COMPUTER SYSTEM

General information		Study design		Study population		Intervention		Outcome	
Study ID	123456789	Study type	Randomized controlled trial	Study location	University Hospital, London	Study duration	12 months	Intervention group	Control group
Study title	The effect of a new drug on the treatment of patients with a specific condition								
Study objectives	To evaluate the efficacy and safety of the new drug compared to the standard treatment.								
Study hypothesis	The new drug will be more effective and safer than the standard treatment.								
Study population	Patients with a specific condition, aged 18-75, who are not on any other medication.								
Study design	Randomized controlled trial, parallel group design.								
Study intervention	The new drug (Intervention group) and the standard treatment (Control group).								
Study outcome	The primary outcome is the percentage of patients achieving a specific clinical endpoint. The secondary outcome is the percentage of patients experiencing adverse effects.								
Study results	The new drug showed a significantly higher percentage of patients achieving the clinical endpoint compared to the standard treatment. The percentage of patients experiencing adverse effects was similar between the two groups.								
Study conclusion	The new drug is more effective and safer than the standard treatment.								

☒ Concurrently Herewith
☐ Date Recorded _____
☐ Reel _____ Frame _____

elects to conduct the prosecution of the application/maintenance of the patent to the exclusion of the inventor(s). The undersigned hereby declares that he has reviewed the above-referenced assignment and hereby declares that, to the best of his knowledge, title is in the Assignee, and further declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true. The assignee hereby revokes any previous powers of attorney and appoints the following to prosecute this application/maintain this patent and transact all business in the Patent and Trademark Office connected therewith:

C. Douglass Thomas	32,947
Irene Kosturakis	33,724
Keith Lutsch	31,851
Joseph Arrambide	39,589
Sarah T. Harris	35,891
Barry D. Blount	35,069
Russell Wong	32,322
T. Grant Ritz	39,819

Please direct all communications to: **Beyer & Weaver, LLP, 620 Hansen Way, Palo Alto, CA 94304, (650) 493-2100**, to the attention of: **C. Douglass Thomas**.

COMPAQ COMPUTER CORPORATION

March 30, 1998

Irene Kosturakis

TITLE: Manager Worldwide Patent Development

Irene Kosturakis
Manager Worldwide Patent Development
Authorized To Sign This Document On Behalf Of
Compaq Computer Corporation
Pursuant To Board Of Directors Resolution
Date July 28, 1989